Human induced pluripotent stem cells: A disruptive innovation

Current Research in Translational Medicine

Volumn 64, Issue 2, 2016, Pages 91-96

  De Vos, J ^a,b,c,d,e   Bouckenheimer, J ^a,b,c   Sansac, C ^a,b,c   Lemaitre J M ^a,b   Assou, S ^a,b,c  

^a HÔPITAL SAINT ELOI   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d LIRMM   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Cell reprogramming; Induced pluripotent stem cells; Pluripotency; Regenerative medicine; Stem cells; Trans differentiation

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

CELL DIFFERENTIATION; CELL FATE; CELL INTERACTION; CELL REGENERATION; CELL STRUCTURE; CELL THERAPY; HUMAN; INDUCED PLURIPOTENT STEM CELL; MEMBRANE ELECTROPHYSIOLOGY; NONHUMAN; NUCLEAR REPROGRAMMING; REGENERATIVE MEDICINE; REVIEW; ANIMAL; CELL AGING; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL LINEAGE; CELL REPROGRAMMING TECHNIQUE; CELL TRANSDIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL THERAPY; MOUSE; ORGAN CULTURE TECHNIQUE; PIG; PRECLINICAL STUDY; PROCEDURES; REJUVENATION; SPECIES DIFFERENCE; TRANSPLANTATION; TRENDS;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINEAGE; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; CELLULAR REPROGRAMMING TECHNIQUES; CELLULAR SENESCENCE; DRUG EVALUATION, PRECLINICAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; ORGAN CULTURE TECHNIQUES; REGENERATIVE MEDICINE; REJUVENATION; SPECIES SPECIFICITY; SWINE; THERAPIES, INVESTIGATIONAL; TRANSCRIPTION FACTORS;

EID: 85009104871     PISSN: None     EISSN: 24523186     Source Type: Journal    
DOI: 10.1016/j.retram.2016.04.001     Document Type: Review

References (96)

1. [1] Evans, M.J., Kaufman, M.H., Establishment in culture of pluripotential cells from mouse embryos. Nature 292:5819 (1981), 154–156.
2. [2] Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 282:5391 (1998), 1145–1147.
3. [3] Gurdon, J.B., Elsdale, T.R., Fischberg, M., Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature 182:4627 (1958), 64–65.
4. [4] Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J., Campbell, K.H., Viable offspring derived from fetal and adult mammalian cells. Nature 385:6619 (1997), 810–813.
5. [5] Cowan, C.A., Atienza, J., Melton, D.A., Eggan, K.C., Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309:5739 (2005), 1369–1373.
6. [6] Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:4 (2006), 663–676.
7. [7] Takahashi, K., Tanabe, K., Ohnuki, M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:5 (2007), 861–872.
8. [8] Okita, K., Ichisaka, T., Yamanaka, S., Generation of germline-competent induced pluripotent stem cells. Nature 448:7151 (2007), 313–317.
9. [9] Wernig, M., Meissner, A., Foreman, R., et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:7151 (2007), 318–324.
10. [10] Yu, J., Vodyanik, M.A., Smuga-Otto, K., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:5858 (2007), 1917–1920.
11. [11] Maherali, N., Sridharan, R., Xie, W., et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1:1 (2007), 55–70.
12. [12] Park, I.-H., Zhao, R., West, J.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451:7175 (2008), 141–146.
13. [13] Science AAFTAO, Nobel Prize in physiology or medicine. Reprogrammed cells earn biologists top honor. Science 338:6104 (2012), 178–179.
14. [14] Yamanaka, S., Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10:6 (2012), 678–684.
15. [15] Choi, J., Lee, S., Mallard, W., et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat Biotechnol 33:11 (2015), 1173–1181.
16. [16] Vallier, L., Putting induced pluripotent stem cells to the test. Nat Biotechnol 33:11 (2015), 1145–1146.
17. [17] Rouhani, F., Kumasaka, N., de Brito, M.C., Bradley, A., Vallier, L., Gaffney, D., Genetic background drives transcriptional variation in human induced pluripotent stem cells. PLoS Genet, 10(6), 2014, e1004432.
18. [18] Hornstein, E., Shomron, N., Canalization of development by microRNAs. Nat Genet 38 (2006), S20–S24.
19. [19] McGrath, J., Solter, D., Inability of mouse blastomere nuclei transferred to enucleated zygotes to support development in vitro. Science 226:4680 (1984), 1317–1319.
20. [20] Cyranoski, D., Stem cells: the black box of reprogramming. Nature 516:7530 (2014), 162–164.
21. [21] Samavarchi-Tehrani, P., Golipour, A., David, L., et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 7:1 (2010), 64–77.
22. [22] Cheloufi, S., Elling, U., Hopfgartner, B., et al. The histone chaperone CAF-1 safeguards somatic cell identity. Nature 528:7581 (2015), 218–224.
23. [23] Soufi, A., Garcia, M.F., Jaroszewicz, A., Osman, N., Pellegrini, M., Zaret, K.S., Pioneer transcription factors target partial DNA motifs on nucleosomes to initiate reprogramming. Cell 161:3 (2015), 555–568.
24. [24] Onder, T.T., Kara, N., Cherry, A., et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483:7391 (2012), 598–602.
25. [25] Tapscott, S.J., Davis, R.L., Thayer, M.J., Cheng, P.F., Weintraub, H., Lassar, A.B., MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 242:4877 (1988), 405–411.
26. [26] Xie, H., Ye, M., Feng, R., Graf, T., Stepwise reprogramming of B cells into macrophages. Cell 117:5 (2004), 663–676.
27. [27] Zhu, S., Rezvani, M., Harbell, J., et al. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature 508:7494 (2014), 93–97.
28. [28] Karagiannis, P., Yamanaka, S., The fate of cell reprogramming. Nat Methods 11:10 (2014), 1006–1008.
29. [29] Morris, S.A., Cahan, P., Li, H., et al. Dissecting engineered cell types and enhancing cell fate conversion via cellnet. Cell 158:4 (2014), 889–902.
30. [30] Warren, L., Manos, P.D., Ahfeldt, T., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:5 (2010), 618–630.
31. [31] Lee, J., Sayed, N., Hunter, A., et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell 151:3 (2012), 547–558.
32. [32] Hou, P., Li, Y., Zhang, X., et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341:6146 (2013), 651–654.
33. [33] Zhao, Y., Zhao, T., Guan, J., et al. A XEN-like state bridges somatic cells to pluripotency during chemical reprogramming. Cell 163:7 (2015), 1678–1691.
34. [34] Lapasset, L., Milhavet, O., Prieur, A., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev 25:21 (2011), 2248–2253.
35. [35] Frobel, J., Hemeda, H., Lenz, M., et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Reports 3:3 (2014), 414–422.
36. [36] Wahlestedt, M., Norddahl, G.L., Sten, G., et al. An epigenetic component of hematopoietic stem cell aging amenable to reprogramming into a young state. Blood 121:21 (2013), 4257–4264.
37. [37] Oh, J., Lee, Y.D., Wagers, A.J., Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat Med 20:8 (2014), 870–880.
38. [38] Lemey, C., Milhavet, O., Lemaitre, J.-M., iPSCs as a major opportunity to understand and cure age-related diseases. Biogerontology 16:4 (2015), 399–410.
39. [39] Liu, G.-H., Suzuki, K., Qu, J., et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8:6 (2011), 688–694.
40. [40] Batista, L.F., Artandi, S.E., Understanding telomere diseases through analysis of patient-derived iPS cells. Curr Opin Genet Dev 23:5 (2013), 526–533.
41. [41] Nissan, X., Blondel, S., Navarro, C., et al. Unique preservation of neural cells in Hutchinson-Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. Cell Rep 2:1 (2012), 1–9.
42. [42] Wu, T., Liu, Y., Wen, D., et al. Histone variant H2A.X. deposition pattern serves as a functional epigenetic mark for distinguishing the developmental potentials of iPSCs. Cell Stem Cell 15:3 (2014), 281–294.
43. [43] Villasante, A., Piazzolla, D., Li, H., Gomez-Lopez, G., Djabali, M., Serrano, M., Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells. Cell Cycle 10:9 (2011), 1488–1498.
44. [44] de Wit, E., Bouwman, B.A.M., Zhu, Y., et al. The pluripotent genome in three dimensions is shaped around pluripotency factors. Nature 501:7466 (2013), 227–231.
45. [45] Carey, B.W., Finley, L.W.S., Cross, J.R., Allis, C.D., Thompson, C.B., Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518:7539 (2015), 413–416.
46. [46] Ramirez, J.M., Bai, Q., Pequignot, M., et al. Side scatter intensity is highly heterogeneous in undifferentiated pluripotent stem cells and predicts clonogenic self-renewal. Stem Cells Dev 22:12 (2013), 1851–1860.
47. [47] Bai, Q., Assou, S., Haouzi, D., et al. Dissecting the first transcriptional divergence during human embryonic development. Stem Cell Rev Rep 8:1 (2012), 150–162.
48. [48] Moretti, A., Bellin, M., Welling, A., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363:15 (2010), 1397–1409.
49. [49] Boulting, G.L., Kiskinis, E., Croft, G.F., et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 29:3 (2011), 279–286.
50. [50] Kajiwara, M., Aoi, T., Okita, K., et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A 109:31 (2012), 12538–12543.
51. [51] Huch, M., Koo, B.-K., Modeling mouse and human development using organoid cultures. Development 142:18 (2015), 3113–3125.
52. [52] Takasato, M., Er, P.X., Chiu, H.S., et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 526:7574 (2015), 564–568.
53. [53] McCracken, K.W., Catá, E.M., Crawford, C.M., et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516:7531 (2014), 400–404.
54. [54] Zhong, X., Gutierrez, C., Xue, T., et al. Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs. Nat Commun, 5, 2014, 4047.
55. [55] Muguruma, K., Nishiyama, A., Kawakami, H., Hashimoto, K., Sasai, Y., Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep 10:4 (2015), 537–550.
56. [56] Lancaster, M.A., Renner, M., Martin, C.-A., et al. Cerebral organoids model human brain development and microcephaly. Nature 501:7467 (2013), 373–379.
57. [57] Takebe, T., Sekine, K., Enomura, M., et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499:7459 (2013), 481–484.
58. [58] Odorico, J.S., Kaufman, D.S., Thomson, J.A., Multilineage differentiation from human embryonic stem cell lines. Stem Cells 19:3 (2001), 193–204.
59. [59] Marchetto, M.C.N., Carromeu, C., Acab, A., et al. A model for neural development and treatment of rett syndrome using human induced pluripotent stem cells. Cell 143:4 (2010), 527–539.
60. [60] Cereso, N., Pequignot, M.O., Robert, L., et al. Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient. Mol Ther Methods Clin Dev, 1, 2014, 14011.
61. [61] McNeish, J., Embryonic stem cells in drug discovery. Nat Rev Drug Discov 3:1 (2004), 70–80.
62. [62] Ryan, S.D., Dolatabadi, N., Chan, S.F., et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 155:6 (2013), 1351–1364.
63. [63] Yamashita, A., Morioka, M., Kishi, H., et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 513:7519 (2014), 507–511.
64. [64] Naryshkin, N.A., Weetall, M., Dakka, A., et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345:6197 (2014), 688–693.
65. [65] Peric, D., Barragan, I., Giraud-Triboult, K., et al. Cytostatic effect of repeated exposure to simvastatin: a mechanism for chronic myotoxicity revealed by the use of mesodermal progenitors derived from human pluripotent stem cells. Stem Cells 33:10 (2015), 2936–2948.
66. [66] Liang, P., Lan, F., Lee, A.S., et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease specific patterns of cardiotoxicity. Circulation 127:16 (2013), 1677–1691.
67. [67] Mason, C., Dunnill, P., A brief definition of regenerative medicine. Regen Med 3:1 (2008), 1–5.
68. [68] Vegas, A.J., Veiseh, O., Gürtler, M., et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med 22:3 (2016), 306–311.
69. [69] Tolosa, L., Caron, J., Hannoun, Z., et al. Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther, 6(1), 2015, 246.
70. [70] Bellamy, V., Vanneaux, V., Bel, A., et al. Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. J Heart Lung Transplant 34:9 (2015), 1198–1207.
71. [71] Sun, J., Mandai, M., Kamao, H., et al. Protective effects of human iPS-derived retinal pigmented epithelial cells in comparison with human mesenchymal stromal cells and human neural stem cells on the degenerating retina in rd1 mice. Stem Cells 33:5 (2015), 1543–1553.
72. [72] Lamba, D.A., Gust, J., Reh, T.A., Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in crx-deficient mice. Cell Stem Cell 4:1 (2009), 73–79.
73. [73] Kriks, S., Shim, J.-W., Piao, J., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480:7378 (2011), 547–551.
74. [74] Scott, C.T., Magnus, D., Wrongful termination: lessons from the geron clinical trial. Stem Cells Transl Med 3:12 (2014), 1398–1401.
75. [75] Menasche, P., Vanneaux, V., Hagège, A., et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J 36:30 (2015), 2011–2017.
76. [76] Schwartz, S.D., Regillo, C.D., Lam, B.L., et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385:9967 (2015), 509–516.
77. [77] Garber, K., RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat Biotechnol 33:9 (2015), 890–891.
78. [78] Hamdi, H., Planat-Benard, V., Bel, A., et al. Long-term functional benefits of epicardial patches as cell carriers. Cell Transplant 23:1 (2014), 87–96.
79. [79] Bai, Q., Desprat, R., Klein, B., Lemaitre, J.-M., De Vos, J., Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective. Curr Gene Ther 13:2 (2013), 93–98.
80. [80] Rashid, T., Kobayashi, T., Nakauchi, H., Revisiting the flight of Icarus: making human organs from PSCs with large animal chimeras. Cell Stem Cell 15:4 (2014), 406–409.
81. [81] Normile, D., Stem cell research. Chimeric embryos may soon get their day in the sun. Science 340:6140 (2013), 1509–1510.
82. [82] Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, M., Studer, L., Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27:3 (2009), 275–280.
83. [83] Kanemura, H., Go, M.J., Nishishita, N., et al. Pigment epithelium-derived factor secreted from retinal pigment epithelium facilitates apoptotic cell death of iPSC. Sci Rep, 3, 2013, 2334.
84. [84] Shalom-Feuerstein, R., Serror, L., Aberdam, E., et al. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET. Proc Natl Acad Sci U S A 110:6 (2013), 2152–2156.
85. [85] Nissan, X., Larribere, L., Saidani, M., et al. Functional melanocytes derived from human pluripotent stem cells engraft into pluristratified epidermis. Proc Natl Acad Sci U S A 108:36 (2011), 14861–14866.
86. [86] Chal, J., Oginuma, M., Tanoury Al, Z., et al. Differentiation of pluripotent stem cells to muscle fiber to model Duchenne muscular dystrophy. Nat Biotechnol 33:9 (2015), 962–969.
87. [87] Smith, M.J., Webber, B.R., Mohtashami, M., Stefanski, H.E., Zúñiga-Pflücker, J.C., Blazar, B.R., In vitro T-cell generation from adult, embryonic, and induced pluripotent stem cells: many roads to one destination. Stem Cells 33:11 (2015), 3174–3180.
88. [88] Kobari, L., Yates, F., Oudrhiri, N., et al. Human induced pluripotent stem cells can reach complete terminal maturation: in vivo and in vitro evidence in the erythropoietic differentiation model. Haematologica 97:12 (2012), 1795–1803.
89. [89] Orlova, V.V., van den Hil, F.E., Petrus-Reurer, S., Drabsch, Y., Dijke Ten, P., Mummery, C.L., Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells. Nat Protoc 9:6 (2014), 1514–1531.
90. [90] Umeda, K., Oda, H., Yan, Q., et al. Long-term expandable SOX9+ chondrogenic ectomesenchymal cells from human pluripotent stem cells. Stem Cell Reports 4:4 (2015), 712–726.
91. [91] Mohsen-Kanson, T., Hafner, A.-L., Wdziekonski, B., et al. Differentiation of human induced pluripotent stem cells into brown and white adipocytes: role of Pax3. Stem Cells 32:6 (2014), 1459–1467.
92. [92] Wong, A.P., Chin, S., Xia, S., Garner, J., Bear, C.E., Rossant, J., Efficient generation of functional CFTR-expressing airway epithelial cells from human pluripotent stem cells. Nat Protoc 10:3 (2015), 363–381.
93. [93] Hannan, N.R.F., Segeritz, C.-P., Touboul, T., Vallier, L., Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc 8:2 (2013), 430–437.
94. [94] Kurmann, A.A., Serra, M., Hawkins, F., et al. Regeneration of thyroid function by transplantation of differentiated pluripotent stem cells. Cell Stem Cell 17:5 (2015), 527–542.
95. [95] Rezania, A., Bruin, J.E., Arora, P., et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 32:11 (2014), 1121–1133.
96. [96] Waddington, C.H., Principles of embryology. 1956, New York.